Hospitals aren’t usually places where oxygen is in short supply. Except in the gut, where a lack of it gives anaerobic pathogens like Clostridioides difficile the perfect hideout. That gap has turned into a multibillion-dollar hole in the healthcare system, one that costs more than five billion dollars annually in the United States and contributes to around twenty-nine thousand deaths each year. LPOXY Therapeutics, Inc. is betting oxygen can do more than keep patients breathing. They believe it can save them from infections that thrive when antibiotics wipe the gut clean.
Founded in 2020 by Dr. Larry Sutton, MD, PhD, LPOXY has been building its answer: SIDIPREV™, an enteric-coated, metered-dose oxygen capsule designed to release in the colon. The science is elegantly blunt, delivering oxygen where C. diff wants none, blocking toxin production, cooling down inflammation, and tilting the odds back in favor of the patient. It is a non-antibiotic approach, which means no tug-of-war with resistance and none of the stewardship headaches that bog down traditional drug rollouts. If it works at scale, hospitals could see fewer recurrences, fewer complications, and fewer penalties under fixed-payment models. Translation: lives saved, costs cut, margins protected.
The company just secured twenty-eight million dollars in Series A financing, led by 5 Horizons Ventures, LLC. This is not a minor seed check. This is a syndicate-backed, Phase III-funding kind of play, capital aimed at fueling the registrational STOP-Cdiff pivotal trial, enrolling roughly five hundred hospitalized patients. The data package inherited from LPOXY’s January acquisition of Xeno Biosciences, regulatory filings, clinical safety data, intellectual property, gives them a head start most biotechs would envy. More than thirty global patents protect SIDIPREV™, with coverage on formulation, dosing, and applications, giving them the moat required for a market this large.
Credit where it is due. Dr. Larry Sutton has spent more than fifteen years navigating infectious disease research and regulatory channels. Now, with the capital and assets in place, the job is clear: run the pivotal trial, lock in FDA’s LPAD and QIDP designations, and scale manufacturing with a CDMO partner ready to deliver commercial supply. On the investment side, Paul Ferguson, Partner and CFO at 5 Horizons Ventures, is stepping in as a key sponsor, aligning financial discipline with a market opportunity too large for cautious half-measures.
This is biotech at its sharpest, repurposing a simple, safe element into a platform that could reset how hospitals approach infection prevention. Oxygen has always been essential for life. LPOXY Therapeutics is making the case it may also be essential for keeping patients alive when antibiotics leave them vulnerable. If SIDIPREV™ delivers, it is not just about lowering numbers on a hospital spreadsheet. It is about changing the baseline of risk for hundreds of thousands of patients who never expected a routine hospital stay to become a fight for survival.
